True North cashes out $2 billion for investors as PE firms step up exits

health focus

Chander, who leads investments in the healthcare and life sciences sector for True North, believes the sector will remain healthy, with quality assets continuing to attract both IPO and strategic interest, even as investors become much more selective about pricing. “This is truly a two-speed IPO market. Some companies are able to price successfully, while others face significant resistance to valuation,” he said.